Expand OCGN Menu
OCGN MENU

OCGN Latest Press Releases

-- August 6, 2026 --

Ocugen Provides Business Update with Second Quarter 2026 Financial Results Globe Newswire 7:02 AM

-- July 31, 2026 --

Ocugen to Participate in Upcoming August Investor Conferences Globe Newswire 7:02 AM

-- July 29, 2026 --

Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration Globe Newswire 7:01 AM

-- July 28, 2026 --

Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results Globe Newswire 4:01 PM

-- July 13, 2026 --

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa Globe Newswire 7:02 AM

-- July 1, 2026 --

Ocugen to Participate in Upcoming July Industry Conferences Globe Newswire 7:00 AM

-- June 2, 2026 --

Ocugen to Participate in Upcoming June Investor and Industry Conferences Globe Newswire 7:03 AM

-- May 14, 2026 --

Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes Globe Newswire 4:30 PM

-- May 13, 2026 --

Ocugen to Participate in Upcoming May Scientific and Investor Conferences Globe Newswire 7:02 AM

-- May 5, 2026 --

Ocugen Provides Business Update with First Quarter 2026 Financial Results Globe Newswire 8:32 AM
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes Globe Newswire 8:12 AM

-- May 4, 2026 --

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes Globe Newswire 4:01 PM

-- April 29, 2026 --

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results Globe Newswire 7:02 AM

-- April 23, 2026 --

Ocugen to Present at April 2026 Investor and Industry Conferences Globe Newswire 7:02 AM

-- April 1, 2026 --

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease Globe Newswire 7:02 AM

-- March 24, 2026 --

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Globe Newswire 7:45 AM

-- March 23, 2026 --

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410-Modifier Gene Therapy for Geographic Atrophy Globe Newswire 7:02 AM
Market Data Delayed 15 Minutes